179 related articles for article (PubMed ID: 37525510)
41. The problem of pain: Additive analgesic effect of tramadol and buprenorphine in a patient with opioid use disorder.
Montalvo C; Genovese N; Renner J
Subst Abus; 2019; 40(2):136-139. PubMed ID: 30835647
[No Abstract] [Full Text] [Related]
42. Availability of Extended-Release Buprenorphine to Treat Opioid Use Disorders Among Medicaid-Covered Patients.
Shover CL
Psychiatr Serv; 2021 Feb; 72(2):225-226. PubMed ID: 32907476
[No Abstract] [Full Text] [Related]
43. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series.
Shearer D; Young S; Fairbairn N; Brar R
Drug Alcohol Rev; 2022 Feb; 41(2):444-448. PubMed ID: 34647379
[TBL] [Abstract][Full Text] [Related]
44. The Shelby Clinic Medication-Assisted Treatment for Opioid Addiction.
Penn CL
J Ark Med Soc; 2016 Aug; 113(2):30-32. PubMed ID: 30047628
[No Abstract] [Full Text] [Related]
45. Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder.
Bhatraju EP; Radick AC; Leroux BG; Kim TW; Samet JH; Tsui JI
Am J Drug Alcohol Abuse; 2023 Jul; 49(4):511-518. PubMed ID: 37369019
[No Abstract] [Full Text] [Related]
46. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
Soyka M; Groß G
Am J Drug Alcohol Abuse; 2021 Sep; 47(5):599-604. PubMed ID: 34407703
[TBL] [Abstract][Full Text] [Related]
47. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
[TBL] [Abstract][Full Text] [Related]
48. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
Jones CM; McCance-Katz EF
Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
[TBL] [Abstract][Full Text] [Related]
49. Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder.
Saunders EC
Am J Psychiatry; 2022 Oct; 179(10):699-701. PubMed ID: 36181331
[No Abstract] [Full Text] [Related]
50. Surgical removal of extended-release buprenorphine depot due to adverse reactions.
Burton A; DeBona DJ; Handzel M; Kelly-Pisciotti S; Qiao M; Rojek D; Acquisto NM
Am J Emerg Med; 2024 Jul; 81():127-128. PubMed ID: 38723364
[TBL] [Abstract][Full Text] [Related]
51. Global opioid agonist treatment: a review of clinical practices by country.
Jin H; Marshall BDL; Degenhardt L; Strang J; Hickman M; Fiellin DA; Ali R; Bruneau J; Larney S
Addiction; 2020 Dec; 115(12):2243-2254. PubMed ID: 32289189
[TBL] [Abstract][Full Text] [Related]
52. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
Balhara YP
J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
[No Abstract] [Full Text] [Related]
53. The case for a medication first approach to the treatment of opioid use disorder.
Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
[No Abstract] [Full Text] [Related]
54. Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies.
Li X; Shorter D; Kosten TR
Expert Opin Pharmacother; 2014 Oct; 15(15):2263-75. PubMed ID: 25171726
[TBL] [Abstract][Full Text] [Related]
55. Buprenorphine Supply, Access, and Quality: Where We Have Come and the Path Forward.
Breen CT; Fiellin DA
J Law Med Ethics; 2018 Jun; 46(2):272-278. PubMed ID: 30147002
[TBL] [Abstract][Full Text] [Related]
56. Buprenorphine Initiation: Low-Dose Methods #457.
Ho JJ; Jones KF; Merlin JS; Sager Z; Childers J
J Palliat Med; 2023 Jun; 26(6):867-869. PubMed ID: 37276524
[No Abstract] [Full Text] [Related]
57. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
58. Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.
Chou R; Ballantyne J; Lembke A
Ann Intern Med; 2019 Sep; 171(6):427-429. PubMed ID: 31450240
[No Abstract] [Full Text] [Related]
59. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
[TBL] [Abstract][Full Text] [Related]
60. Emergency Department Initiation of Buprenorphine for Opioid Use Disorder: Current Status, and Future Potential.
Fox L; Nelson LS
CNS Drugs; 2019 Dec; 33(12):1147-1154. PubMed ID: 31552608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
